While the Absorb bioresorbable vascular scaffold had target vessel failure rates similar to conventional metallic stents in an all-comers trial, it yet again highlighted the risk of device thrombosis.
Trending:
Absorb's Thrombosis Troubles Persist in All-Comers Trial